The effect of P-glycoprotein inhibition and activation on the absorption and serum levels of cyclosporine and tacrolimus in rats

Advances in Clinical and Experimental Medicine

Volumn 25, Issue 2, 2016, Pages 237-242

  Yigitaslan, Semra ^a   Erol, Kevser ^a   Cengelli, Cigdem ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Cyclosporine; Everted sac; P glycoprotein; Tacrolimus

Indexed keywords

CYCLOSPORIN; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; TACROLIMUS; VERAPAMIL; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG RESPONSE; ILEUM; IN VITRO STUDY; IN VIVO STUDY; JEJUNUM; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SMALL INTESTINE ABSORPTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; SMALL INTESTINE; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; CYCLOSPORINE; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; IN VITRO TECHNIQUES; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; P-GLYCOPROTEIN; RATS, SPRAGUE-DAWLEY; RIFAMPIN; TACROLIMUS; VERAPAMIL;

EID: 84969194947     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/35254     Document Type: Article

References (29)

1. Hamman JH, Demana PH, Olivier EI: Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights 2007, 2, 71-81.
2. Mouly S, Paine MF: P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003, 20, 1595-1599.
3. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M: Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 1999, 289, 149-155.
4. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Lennernas H: Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007, 4, 252-257.
5. Nakayama A, Saitoh H, Oda M, Takada M, Aungst BJ: Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 2000, 11, 317-324.
6. Kilic FS, Batu O, Sirmagul B, Yildirim E, Erol K: Intestinal absorption of digoxin and interaction with nimodipine in rats. Pol J Pharmacol 2004, 56, 137-141.
7. Leu BL, Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995, 35, 432-436.
8. Takano M, Yumoto R, Murakami T: Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006, 109, 137-161.
9. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992, 267, 24248-24252.
10. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997, Suppl 40, 13-19.
11. Finch CK, Chrisman CR, Baciewicz AM, Self TH: Rifampin and rifabutin drug interactions: An update. Arch Intern Med 2002, 162, 985-992.
12. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 2003, 42, 819-850.
13. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Hebert MF: Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997, 62, 41-49.
14. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation. Br J Pharmacol 1996, 118, 1841-1847.
15. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268, 6077-6080.
16. Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M: Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig 2014, 34, 651-659.
17. Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P: Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014, 34, 173-182.
18. Fudin J, Fontenelle DV, Payne A: Rifampin reduces oral morphine absorption: A case of transdermal buprenorphine selection based on morphine pharmacokinetics. J Pain Palliat Care Pharmacother 2012, 26, 362-367.
19. Wilson TH, Wiseman G: The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. J Physiol 1954, 123, 116-125.
20. Barthe L, Woodley J, Houin G: Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999, 13, 154-168.
21. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G: Kinetic profiling of P-glycoproteinmediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001, 296, 584-591.
22. Hashimoto Y, Sasa H, Shimomura M, Inui K: Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998, 15, 1609-1613.
23. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S: Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002, 91, 719-729.
24. Saitoh H, Saikachi Y, Kobayashi M, Yamaguchi M, Oda M, Yuhki Y, Aungst BJ: Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci 2006, 28, 34-42.
25. Chiou WL, Chung SM, Wu TC: Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm Res 2000, 17, 205-208.
26. Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997, 27, 201-214.
27. Flepisi BT, Bouic P, Sissolak G, Rosenkranz B: Drug-drug interactions in HIV positive cancer patients. Biomed Pharmacother 2014, Apr. 28. pii: S0753-3322 (14) 00058-4. DOI: 10.1016/j.biopha.2014.04.010
28. Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer 2006, 6, 546-558.
29. Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT: Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol 2014, 77, 1039-1050.